Follicular Lymphoma

• CLINICAL_TRIALS research · 2025-06-06
  Clinical Trial Update: Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

  A clinical trial is investigating the effectiveness and safety of the CAR-T therapy tisagenlecleucel in Brazilian patients with B-lymphocyte…

• FDA approval · 2025-05-22
  FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)

  FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…

• CLINICAL_TRIALS trial_result · 2025-05-16
  Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…

• CLINICAL_TRIALS trial_result · 2025-05-14
  Clinical Trial Update: Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma [Phase 3]

  A Phase 3 trial evaluating the combination of rituximab and lenalidomide in previously untreated follicular lymphoma has completed enrollmen…

• CLINICAL_TRIALS trial_result · 2025-05-14
  Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-05-13
  Clinical Trial Update: Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy [EARLY_Phase 1]

  A Phase 1 trial of ibrutinib in patients with follicular lymphoma who did not achieve a complete response to initial chemoimmunotherapy has …

• CLINICAL_TRIALS trial_result · 2025-05-09
  Clinical Trial Update: Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

  A non-interventional study (URBAN) evaluated obinutuzumab for untreated follicular lymphoma and has completed with results posted.

• CLINICAL_TRIALS research · 2025-05-08
  Clinical Trial Update: Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A [Phase 2]

  This phase 2 trial compares Obinutuzumab with CHOP versus Obinutuzumab with Bendamustine in newly diagnosed Follicular lymphoma Grade 3A. Th…

• CLINICAL_TRIALS research · 2025-05-07
  Clinical Trial Update: Zanubrutinib Combined With G-CVP in Previously Untreated FL [Phase 2]

  Phase 2 clinical trial update on zanubrutinib combined with G-CVP for previously untreated follicular lymphoma; recruitment is ongoing in Ch…

• CLINICAL_TRIALS withdrawal · 2025-05-06
  Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]

  Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.

• CLINICAL_TRIALS trial_result · 2025-04-24
  Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

  Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …

• CLINICAL_TRIALS research · 2025-04-24
  Clinical Trial Update: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma [Phase 2]

  A Phase 2 clinical trial is evaluating the combination of Brentuximab Vedotin and Bendamustine for relapsed or refractory follicular lymphom…

• CLINICAL_TRIALS trial_result · 2025-04-18
  Clinical Trial Update: A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients [Phase 3]

  A Phase 3 clinical trial evaluating rituximab plus chemotherapy for follicular lymphoma in elderly patients has completed.

• CLINICAL_TRIALS trial_result · 2025-04-18
  Clinical Trial Update: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma [Phase 2]

  A Phase 2 trial evaluating pembrolizumab in combination with rituximab or obinutuzumab for relapsed or refractory follicular lymphoma or dif…

• CLINICAL_TRIALS trial_result · 2025-04-16
  Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

  Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…

• CLINICAL_TRIALS research · 2025-04-15
  Clinical Trial Update: Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma [Phase 2]

  This clinical trial update outlines a Phase 2 study of zanubrutinib plus GCVP (obinutuzumab, cyclophosphamide, vindesine, prednisolone) in p…

• CLINICAL_TRIALS trial_result · 2025-04-11
  Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…

• CLINICAL_TRIALS research · 2025-04-10
  Clinical Trial Update: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 2]

  This is a multi-center Phase 2 study evaluating oral Abexinostat as monotherapy for relapsed or refractory follicular lymphoma. The trial is…

• CLINICAL_TRIALS research · 2025-04-10
  Clinical Trial Update: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 2]

  A Phase 2 trial evaluating Abexinostat in relapsed or refractory Follicular lymphoma is active but not recruiting.

• CLINICAL_TRIALS trial_result · 2025-04-06
  Clinical Trial Update: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma [Phase 2]

  Phase 2 trial of HMPL-689 for relapsed/refractory marginal zone lymphoma and follicular lymphoma has completed.

• CLINICAL_TRIALS research · 2025-04-06
  Clinical Trial Update: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies [Phase 1]

  Phase 1 study evaluating autologous CD19 CAR-T cell therapy SYNCAR-001 with orthogonal IL-2 STK-009 in CD19-positive hematologic malignancie…

• CLINICAL_TRIALS trial_result · 2025-04-04
  Clinical Trial Update: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. [Phase 3]

  Phase 3 trial evaluating tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in relapsed/refractory f…

• CLINICAL_TRIALS trial_result · 2025-03-26
  Clinical Trial Update: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma [Phase 1]

  Phase 1 trial evaluating avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy in patients with relapsed or refractory diffuse large …

• CLINICAL_TRIALS research · 2025-03-21
  Clinical Trial Update: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy [Phase 2]

  Phase 2 frontline trial evaluating atezolizumab plus obinutuzumab with or without radiotherapy for follicular lymphoma; current status is ac…

• CLINICAL_TRIALS trial_result · 2025-03-11
  Clinical Trial Update: Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

  A US-based observational lymphoma registry sponsored by Celgene has been terminated.